PACIFIC-5: a phase III clinical trial of consolidation durvalumab in patients with unresectable stage III NSCLC and no progression after concurrent or sequential chemoradiotherapy Authors: Yi-Long Wu, Lin Wu, Nan Bi, Timucin Cil, Hong Ge, Zhengfei Zhu, Chih-Liang Wang, Wei Zhang, Dongqing Lv, E Mingyan, Jianguo Sun, Yi Pan, Maciej Krzakowski, Mustafa Dikilitas, Mehmet Ali Nahit Sendur, Young-Chul Kim, Yanjiao Yang, Rui Mao, Biao Zhang, Luhua Wang Published: 2025 ABSTRACT AbstractBackgroundConsolidation durvalumab following no progression on concurrent chemoradiotherapy (cCRT) is standard of care for unresectable stage III non-small-cell lung cancer (NSCLC). However, in clinical practice many patients receive sequential CRT (sCRT). The PACIFIC-5 trial aimed to evaluate the efficacy and safety of consolidation durvalumab for unresectable stage III NSCLC following no progression on cCRT or sCRT.MethodsThis randomised, double-blind, placebo-controlled, phase III trial enrolled patients aged ≥ 18 years with unresectable stage III NSCLC, regardless of PD-L1 expression or sensitising EGFR or ALK aberrations, without disease progression after cCRT or sCRT. Patients were randomised (2:1) to durvalumab 1500 mg or placebo intravenously every 4 weeks (stratified by tumour PD-L1 expression and prior treatment) until disease progression, unacceptable toxicity, or consent withdrawal. The primary endpoint was progression-free survival (PFS) by blinded independent central review in the modified intention-to-treat population (mITT). Secondary endpoints included overall survival (OS) in the mITT and safety. The safety analysis set include patients who received at least one dose of study treatment.ResultsOf 407 patients randomised to receive durvalumab (n = 272) or placebo (n = 135), 405 received at least one dose of durvalumab (n = 271) or placebo (n = 134). The mITT comprised 381 patients randomised to durvalumab (n = 252) or placebo (n = 129). Durvalumab showed statistically significant improvement in PFS versus placebo in the mITT (median [95% confidence interval {CI}], 14.0 [10.9–18.0] vs. 6.5 [5.4–13.8] months; hazard ratio [95% CI], 0.75 [0.58–0.99]; p = 0.038). There was a trend toward improved OS with durvalumab versus placebo in the mITT (median [95% CI], 38.3 [28.9–42.8] vs. 32.5 [20.6–40.4] months; hazard ratio [95% CI], 0.87 [0.66–1.17]; p = 0.346 [interim analysis]). Among the safety analysis set, maximum grade 3 or 4 adverse events of any cause occurred in 26.9% (73/271) and 23.9% (32/134) and 1.5% (4/271) and 0% (0/134) had treatment-related adverse events leading to death for durvalumab and placebo, respectively.ConclusionsPACIFIC-5 met its primary endpoint of improved PFS after either cCRT or sCRT. Follow-up for overall survival is ongoing.Trial registrationNCT03706690.Supplementary InformationThe online version contains supplementary material available at 10.1186/s13045-025-01768-1.Keywords: Non-small-cell lung cancer, Immunotherapy, Chemoradiotherapy, Clinical trial , Phase III, Durvalumab Introduction Lung cancer is a leading cause of cancer-related morbidity and mortality worldwide, with an estimated 2.5 million new cases (12.4% of all new cancers) in 2022 [1]. Non-small-cell lung cancer (NSCLC) accounts for the majority (>80%) of all lung cancers, and around a third of patients with NSCLC present with unresectable stage III disease [2–4]. The standard, globally recommended curative-intent treatment for fit patients with unresectable stage III NSCLC includes definitive concurrent chemoradiotherapy (cCRT), involving the simultaneous administration of radiotherapy with platinum-doublet chemotherapy [5–7]. For patients whose disease does not progress during cCRT, the recommended treatment strategy is the administration of durvalumab, a programmed cell death ligand-1 (PD-L1) inhibitor, as consolidation therapy for up to 12 months [5–8]. The efficacy and safety of durvalumab as consolidation therapy in patients with unresectable stage III NSCLC and no disease progression after platinum-based cCRT was evaluated in the phase III PACIFIC trial (NCT02125461), which demonstrated significant improvements in progression-free survival (PFS) (hazard ratio [HR], 0.52; 95% confidence interval [CI], 0.42–0.65; p < 0.001) and overall survival (OS) (HR, 0.68; 95% CI, 0.53–0.87; p = 0.0025) with durvalumab versus placebo [9–11]. Durvalumab was associated with a manageable safety profile (maximum-grade 3 or 4 adverse events [AEs] of any cause increased by 4.4% in the durvalumab group compared with the placebo group) and no detrimental impact on patient-reported outcomes (PROs) compared with placebo [9, 10, 12]. Long-term follow-up from PACIFIC demonstrated that the benefits of durvalumab were sustained over time: the 5-year PFS rates were 33.1% versus 19.0% with durvalumab versus placebo, and the 5-year OS rates were 42.9% versus 33.4%, respectively [11]. While it has been well established that cCRT (defined in the current report as ≥ 2 overlapping cycles of chemotherapy and radiotherapy) improves the OS of patients with stage III NSCLC compared with sequential CRT (sCRT), many older patients, and patients with comorbidities, still receive sCRT in clinical practice, often due to concerns about tolerability [13–15]. For example, in a meta-analysis of randomised trials directly comparing cCRT versus sCRT, cCRT was found to increase acute oesophageal toxicity (grade 3–4) from 4% to 18% with a relative risk of 4.9 (95% CI, 3.1–7.8; p < 0.001) [13]. As patients receiving sCRT were not enrolled in the PACIFIC trial, there remains a lack of evidence for the benefit of consolidation durvalumab after sCRT in this setting [15]. Moreover, there is an unmet need for prospective data regarding consolidation durvalumab in regions not heavily represented in previous studies, such as China, Russia, and other regions in Asia [9, 10, 16]. Here, we report data from PACIFIC-5 (NCT03706690), a global, randomised, double-blind, placebo-controlled, multicentre phase III trial designed to assess the efficacy and safety of consolidation durvalumab in a broader population of patients with unresectable stage III NSCLC whose disease had not progressed after cCRT or sCRT. Methods Patients Eligible patients were ≥ 18 years of age and had World Health Organization (WHO)/Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0 or 1, histologically or cytologically confirmed unresectable stage III NSCLC (according to Version 8 of the International Association for the Study of Lung Cancer Staging Manual in Thoracic Oncology [17]), and no progression following definitive, platinum-based cCRT or sCRT, which must have been completed 1–28 days prior to the first dose of study drug. Positron emission tomography/computed tomography (PET/CT), magnetic resonance imaging (MRI) of the brain, and endobronchial ultrasound were encouraged, but not required as they may not have been available in all sites or countries, at diagnosis. Patients must have had documented epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) status (locally or centrally) at screening and documented tumour PD-L1 status prior to randomisation (assessed at a reference laboratory using the VENTANA PD-L1 [SP263] immunohistochemistry assay). Detailed inclusion and exclusion criteria are provided in the protocol (Supplementary Appendix). For cCRT, eligible patients must have received ≥ 2 cycles of platinum-based chemotherapy concurrent with radiotherapy, and the last dose of chemotherapy must have been prior to, or concurrent with, the final dose of radiotherapy. Consolidation chemotherapy after radiotherapy was not permitted, but ≤ 2 cycles of induction chemotherapy prior to cCRT was acceptable. For sCRT, patients must have received ≥ 2 cycles of platinum-based chemotherapy before radiotherapy, and the interval between administration of the last dose of chemotherapy regimen and start of radiotherapy must have been ≤ 6 weeks. For both cCRT and sCRT, the platinum-based chemotherapy regimen must have contained cisplatin or carboplatin and one of the following agents: etoposide, vinblastine, vinorelbine, a taxane (paclitaxel or docetaxel), or pemetrexed, according to local standard of care regimens (gemcitabine was not included). Patients must also have received a total radiotherapy dose of 60 Gy ± 10% (54 to 66 Gy) during CRT. Study sites were encouraged to adhere to the following mean organ radiation dosing: mean lung dose must be < 20 Gy (Gy), and/or V20 must be < 35%; mean oesophagus dose must be < 34 Gy; heart V45 must be < 35%, or V30 must be < 50%. Finally, with enrolment ongoing, the PACIFIC-5 study protocol was amended (at version 5) to exclude from primary and key secondary analyses patients who had documented test results that confirmed the presence of a sensitising EGFR mutation or ALK translocation (both confirmed by local or central testing). This amendment was based on the emergence of targeted therapies for patients with EGFR and ALK aberrations and emerging results from PACIFIC showing uncertain benefit among patients with EGFR mutations [18–20]. Trial design and treatment Patients with no progression following definitive, platinum-based cCRT or sCRT were randomly assigned (2:1 ratio) in a double-blind manner to receive either durvalumab 1500 mg or placebo administered intravenously every 4 weeks until disease progression, toxicity, or withdrawal of consent. No crossover was allowed. Randomisation was stratified according to PD-L1 expression on tumour cells (TC; < 1% vs. ≥ 1%) and prior therapy (cCRT versus sCRT) (Fig. S1 in the Supplementary Appendix). Randomisation was carried out via interactive voice response system using a single randomisation list for each randomisation strata, generated by a computer software program that incorporates a standard procedure for generating randomisation numbers. A blocked randomisation was generated, with all centres using the same lists to minimise imbalance in the number of participants assigned to each treatment arm. The trial was designed by the sponsor, AstraZeneca. All patients provided written informed consent, and an independent data monitoring committee monitored efficacy and safety. The protocol and all amendments were approved by the relevant ethics committees or institutional review boards, and the trial was performed in accordance with the Declaration of Helsinki, the International Council for Harmonization Good Clinical Practice guidelines, and all applicable laws and regulations. All investigators were responsible for the collection of data. All authors participated in writing the manuscript and provided approval to submit the manuscript for publication. The authors vouch for the accuracy and completeness of the data and for the fidelity of the trial to the protocol. Medical writing assistance, including development of the initial draft of the manuscript, was funded by the sponsor. Endpoints and assessments The primary endpoint was PFS (evaluated by blinded independent central review [BICR] per Response Evaluation Criteria in Solid Tumors [RECIST], version [v]1.1) in the modified intention-to-treat (mITT) population, which excluded patients with documented EGFR or ALK aberrations. PFS was defined as the time from the date of randomisation until the date of objective disease progression or death (by any cause in the absence of progression). The key secondary endpoint was OS in the mITT. OS was defined as the time from the date of randomisation until death due to any cause. Other secondary endpoints included PFS (as assessed by BICR) and OS in all randomised patients (intention-to-treat [ITT] population), OS rate at 24 months following randomisation, objective response rate (ORR) by BICR, duration of response (DoR) by BICR, PFS rate at 12 and 18 months following randomisation by BICR, time from randomisation to second progression (PFS2) by local assessment, and time to death or distant metastasis (TTDM) by BICR. On-study tumour assessments (CT or MRI) occurred at baseline, then every 8 weeks for the first 48 weeks after randomisation and every 12 weeks thereafter until confirmed RECIST v1.1-defined radiological progression plus one or more additional follow-up scans for confirmation of progression, the end of study, death, study discontinuation, or sponsor decision, whichever occurred first. Safety was monitored throughout the trial and assessed in all the patients who had received at least one dose of any trial treatment or placebo (the safety analysis set). AEs were collected from screening until 90 days after the last dose of study drug and documented according to the Medical Dictionary for Regulatory Activities, v26.1, and graded with the use of National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), v5.0. Because variable and overlapping presentations make it challenging to precisely differentiate between radiation pneumonitis and immune-mediated pneumonitis, AEs of pneumonitis were analysed and presented as the grouped term ‘pneumonitis or radiation pneumonitis’ [21, 22]. Statistical analysis We planned that 400 eligible patients would undergo randomisation (2:1 ratio) in the ITT population, including 375 patients in the mITT population, which excluded patients with documented EGFR or ALK alterations who were enrolled before a protocol amendment. The primary PFS (mITT) analysis data cut-off (DCO) was planned to occur when either of the following conditions were first met: reaching approximately 262 BICR PFS events across the durvalumab and placebo treatment arms (approximately 70% maturity) in the mITT population or approximately 28 months follow-up from last patient randomised to the study. As a result, the planned primary PFS analysis had ≥ 90% power to demonstrate a HR of 0.65 with a 2-sided significance level of 5%. The smallest treatment difference that would be statistically significant was a HR of 0.773. Medians and landmark rates for PFS and OS were calculated using the Kaplan-Meier technique. CIs for median PFS and OS were derived based on the Brookmeyer-Crowley method with log-log transformation. The PFS and OS HRs and associated CIs were calculated using a stratified Cox proportional hazards model, adjusting for the level of PD-L1 expression (< 1% vs. ≥ 1%) and prior therapy (cCRT or sCRT), with treatment as the only covariate, ties handled by Efron approach, and CI calculated using a profile likelihood approach. The 2-sided p-values were obtained using the stratified log-rank test, adjusting for the level of PD-L1 expression and prior therapy. Subgroup analyses were performed using the same methodology as for the overall PFS and OS analyses, with the exception that unstratified Cox proportional hazards models and unstratified log-rank tests were used. PFS2 and TTDM were assessed using the same methodology as for PFS and OS. Safety data are summarised descriptively. No interim analyses of PFS and up to two of OS were planned. The alpha level for survival endpoints was controlled using the Lan-DeMets spending function that approximates an O’Brien-Fleming approach [23]. A hierarchical testing procedure was used to strongly control the overall 2-sided type I error at 5%, which was firstly assigned to the primary endpoint, PFS in the mITT (Fig. S2). If PFS in the mITT was significant at the primary analysis, the alpha was recycled to the secondary endpoint of OS in the mITT (alpha level 5%). If OS in the mITT was significant at the interim or final analysis, the alpha was further recycled to PFS in the ITT (alpha level 5%). If PFS in the ITT was significant, the alpha was finally recycled to OS in the ITT (alpha level 5%). Results Patients From 27 November 2018 through 17 January 2022, 773 patients were enrolled and 407 were randomly assigned to receive durvalumab (n = 272) or placebo (n = 135) across 71 sites in mainland China (33 sites), Russia (10 sites), Taiwan (7 sites), Turkey (6 sites), Poland (4 sites), India (3 sites), Philippines (3 sites), Republic of Korea (3 sites), Hong Kong (1 site), and Mexico (1 site; Fig. 1). All randomised patients were included in the ITT; the mITT comprised 381 patients without EGFR or ALK aberrations who had been randomised to receive durvalumab (n = 252) or placebo (n = 129); and the safety analysis set included 405 patients who had received at least one dose of durvalumab (n = 271) or placebo (n = 134). Consort diagram. *Informed consent received. †The mITT population comprises the ITT population minus patients with documented EGFR (durvalumab arm, n = 12; placebo arm, n = 4) or ALK (durvalumab arm, n = 7; placebo arm, n = 2) aberrations or unknown EGFR (durvalumab arm, n = 1; placebo arm, n = 0) or ALK (both arms, n = 0) status. ‡Derived category taking priority over other categories; defined based on reason for discontinuation containing ‘COVID’. §The safety analysis set includes all randomised patients who received at least one dose of study treatment. Abbreviations: ALK, anaplastic lymphoma kinase; COVID-19, coronavirus disease of 2019; DCO. data cut-off; EGFR, epidermal growth factor receptor; ITT, intention-to-treat; mITT, modified intention-to-treat Baseline demographics and disease characteristics were comparable between the ITT and mITT (Table 1). In the mITT, median age was 63.0 years in both arms. In the durvalumab versus placebo arms of the mITT, most patients were male (92.1% vs. 88.4%) and Asian (71.4% vs. 72.9%) with squamous histology (69.8% vs. 65.1%), PD-L1 TC ≥ 1% (59.9% vs. 60.5%), and a history of smoking (84.9% vs. 88.4%). WHO/ECOG PS of 1 (68.3% vs. 55.0%) and stage IIIC disease (23.4% vs. 14.7%) were more prevalent in the durvalumab versus placebo arms of the mITT. Prior radiotherapy and chemotherapy details were similar between arms (Table 1); 66.7% versus 69.8% of patients in the durvalumab versus placebo arms of the mITT had received cCRT, and most (64.7% vs. 65.1%) had a best response to prior CRT of partial response. Table 1Patient characteristics in the mITT and ITTmITT (N = 381)ITT (N = 407)Durvalumab(n = 252)Placebo(n = 129)Durvalumab(n = 272)Placebo(n = 135)Median age (range), years63.0 (39–80)63.0 (33–79)62.5 (35–80)63.0 (33–79)Age category, n (%) < 50 years17 (6.7)5 (3.9)21 (7.7)6 (4.4) ≥ 50 to < 65 years129 (51.2)73 (56.6)139 (51.1)77 (57.0) ≥ 65 to < 75 years91 (36.1)45 (34.9)96 (35.3)46 (34.1) ≥ 75 years15 (6.0)6 (4.7)16 (5.9)6 (4.4)Sex, n (%) Male232 (92.1)114 (88.4)247 (90.8)117 (86.7) Female20 (7.9)15 (11.6)25 (9.2)18 (13.3)Race, n (%) Asian180 (71.4)94 (72.9)197 (72.4)97 (71.9) White72 (28.6)35 (27.1)75 (27.6)38 (28.1)Smoking status, n (%) Current of former214 (84.9)114 (88.4)227 (83.5)116 (85.9) Never38 (15.1)15 (11.6)45 (16.5)19 (14.1)Median (range) time from last dose of radiation to randomisation, days23.0 (3–42)24.0 (7–32)23.0 (3–42)24.0 (7–33)Time from last dose of radiation to randomisation group, n (%) < 14 days26 (10.3)14 (10.9)28 (10.3)16 (11.9) ≥ 14 days226 (89.7)115 (89.1)244 (89.7)119 (88.1)Prior CRT, n (%) Concurrent168 (66.7)90 (69.8)182 (66.9)92 (68.1) Sequential84 (33.3)39 (30.2)90 (33.1)43 (31.9)Best response to prior CRT, n (%) Complete response01 (0.8)01 (0.7) Partial response163 (64.7)84 (65.1)176 (64.7)85 (63.0) Stable disease89 (35.3)44 (34.1)96 (35.3)49 (36.3)Platinum-based chemotherapy Cisplatin122 (48.4)64 (49.6)132 (48.5)66 (48.9) Carboplatin124 (49.2)62 (48.1)133 (48.9)65 (48.1) Cisplatin and carboplatin6 (2.4)3 (2.3)7 (2.6)4 (3.0)Definitive radiotherapy*252 (100)129 (100)272 (100)135 (100)Total radiation dose† n 256132276138 Mean (SD), Gy60.2 (6.11)59.7 (7.61)60.2 (5.95)59.7 (7.45) Median (range), Gy60.0 (10–66)60.0 (5–66)60.0 (10–66)60.0 (5–66)Total radiation dose, n (%)† < 54 Gy3 (1.2)3 (2.3)3 (1.1)3 (2.2) ≥ 54 to ≤ 66 Gy250 (99.2)129 (100)270 (99.3)135 (100) > 66 Gy to ≤ 74 Gy0000 > 74 Gy0000PD-L1 status, n (%) TC < 1%101 (40.1)51 (39.5)107 (39.3)53 (39.3) TC ≥ 1%151 (59.9)78 (60.5)165 (60.7)82 (60.7)ECOG/WHO PS, n (%) 0 – normal activity80 (31.7)58 (45.0)88 (32.4)62 (45.9) 1 – restricted activity172 (68.3)71 (55.0)184 (67.6)73 (54.1)AJCC staging at study entry, n (%) IIIA77 (30.6)45 (34.9)86 (31.6)48 (35.6) IIIB116 (46.0)64 (49.6)124 (45.6)67 (49.6) IIIC59 (23.4)19 (14.7)62 (22.8)19 (14.1) IV01 (0.8)01 (0.7)Histology at study entry, n (%) Squamous176 (69.8)84 (65.1)182 (66.9)85 (63.0) Non-squamous76 (30.2)45 (34.9)90 (33.1)50 (37.0)EGFR mutation Negative252 (100)129 (100)259 (95.2)131 (97.0) Positive0012 (4.4)4 (3.0) Unknown001 (0.4)0ALK rearrangement Negative252 (100)129 (100)265 (97.4)133 (98.5) Positive007 (2.6)2 (1.5) Unknown0000EGFR mutation or ALK rearrangement Negative252 (100)129 (100)252 (92.6)129 (95.6) Positive0019 (7.0)6 (4.4) Unknown001 (0.4)0AJCC, American Joint Committee on Cancer; ALK, anaplastic lymphoma kinase; COVID-19, coronavirus disease of 2019; CRT, chemoradiotherapy; ECOG, Eastern Cooperative Oncology Group; EGFR, epidermal growth factor receptor; Gy, gray; ITT, intention-to-treat; mITT, modified intention-to-treat; PD-L1, programmed cell death ligand-1; PS, performance status; SD, standard deviation; TC, tumour cell expression; WHO, World Health Organisation*Counts the number of unique patients that received prior definitive radiotherapy†Summary may include multiple prior radiotherapies received by the same patient Patient characteristics in the mITT and ITT AJCC, American Joint Committee on Cancer; ALK, anaplastic lymphoma kinase; COVID-19, coronavirus disease of 2019; CRT, chemoradiotherapy; ECOG, Eastern Cooperative Oncology Group; EGFR, epidermal growth factor receptor; Gy, gray; ITT, intention-to-treat; mITT, modified intention-to-treat; PD-L1, programmed cell death ligand-1; PS, performance status; SD, standard deviation; TC, tumour cell expression; WHO, World Health Organisation *Counts the number of unique patients that received prior definitive radiotherapy †Summary may include multiple prior radiotherapies received by the same patient All but one patient in the durvalumab (99.6%) and placebo (99.2%) arms of the mITT received study treatment (Fig. 1). Overall, 80.9% and 82.8% of patients in the mITT discontinued durvalumab or placebo, most commonly due to progressive disease (53.4% vs. 66.4%); 14.3% of patients in the durvalumab arm and 7.0% of patients in the placebo arm of the mITT discontinued study treatment due to an AE. Patients received a median 12.0 cycles of durvalumab or 7.0 doses of placebo, and median actual treatment duration was 48.4 versus 28.3 months with durvalumab versus placebo (Table S1). Approximately half (49.1%) of patients in the durvalumab arm received at least one year (i.e., 13 cycles) of treatment, and almost a third (29.9%) remained on treatment at 2 years (i.e., 26 cycles). After discontinuation of study treatment, 165/381 patients in the mITT received subsequent anticancer therapy: 95/252 (37.7%) patients who received durvalumab and 70/129 (54.3%) patients who received placebo. The most common subsequent anticancer therapies were chemotherapy (durvalumab, 31.3% [n = 79]; placebo, 38.8% [n = 50]) and immunotherapy (durvalumab, 9.5% [n = 24]; placebo, 17.8% [n = 23]). Efficacy There was a statistically significant improvement in the primary end point, PFS in the mITT, with durvalumab versus placebo (Fig. 2A). In the mITT, median follow-up among patients censored for PFS was 35.7 months in the durvalumab arm and 30.5 months in the placebo arm. Median PFS (95% CI) was 14.0 (10.9–18.0) months with durvalumab versus 6.5 (5.4–13.8) months with placebo (stratified HR, 0.75; 95% CI, 0.58–0.99; p = 0.038). Similar results were observed in the ITT, though significance was not formally assessed per the hierarchical testing procedure (Fig. S3). The 12-, 18-, and 24-month PFS rates in the mITT were 53.6%, 43.4%, and 39.9% with durvalumab versus 42.7%, 34.1%, and 30.2% with placebo. (A) PFS by BICR and (B) OS in the mITT. Median and landmark PFS and OS rates were calculated using the Kaplan-Meier technique. CIs for median PFS and OS were derived based on the Brookmeyer-Crowley method with log-log transformation. The HRs and associated CIs were calculated using a stratified Cox proportional hazards model, adjusting for the level of PD-L1 expression and prior therapy, with treatment as the only covariate, ties handled by Efron approach, and CI calculated using a profile likelihood approach. The 2-sided p-values were obtained using the stratified log-rank test, adjusting for the level of PD-L1 expression and prior therapy. HR < 1 favours durvalumab versus placebo. Abbreviations: BICR, blinded independent central review; CI, confidence interval; HR, hazard ratio; mITT, modified intention-to-treat; mo, months; OS, overall survival; PD-L1, programmed death ligand-1; PFS, progression-free survival; pts, patients PFS HRs trended toward benefit with durvalumab across most pre-specified subgroups in the mITT, though 95% CIs crossed one with few exceptions (Fig. S4). Similar benefit was observed after cCRT (HR, 0.76; 95% CI, 0.55–1.06) and sCRT (HR, 0.75; 95% CI, 0.49–1.18) in the mITT (Fig. 3). The exceptions to this were observed among patients with PD-L1 TC < 1% (HR, 0.97; 95% CI, 0.63–1.53) or non-squamous histology (HR, 1.07; 95% CI, 0.66–1.80) and among those who received cisplatin (HR, 0.98; 95% CI, 0.66–1.47), though in each case, the median PFS for the placebo arm (PD-L1 TC < 1%: 13.6 months; non-squamous histology: 19.9 months; cisplatin: 13.8 months) was inconsistent with the median PFS for the placebo arm of the mITT (6.5 months). PFS among patients who received (A) cCRT or (B) sCRT in the mITT. Median and landmark PFS rates were calculated using the Kaplan-Meier technique. CIs for median PFS were derived based on the Brookmeyer-Crowley method with log-log transformation. HRs and CIs for analyses were calculated via unstratified Cox proportional hazards model, with treatment as the only covariate, ties handled by Efron approach, and CIs calculated using a profile likelihood approach. The 2-sided p-value was obtained using the unstratified log-rank test. HR < 1 favours durvalumab versus placebo. *Per eCRF. Abbreviations: cCRT, concurrent chemoradiotherapy; CI, confidence interval; eCRF, electronic case report form; HR, hazard ratio; mITT, modified intention-to-treat; mo, months; sCRT, sequential chemoradiotherapy At this first interim analysis, there was a trend toward improved OS in the mITT with durvalumab versus placebo (Fig. 2B). In the mITT, median follow-up among patients censored for OS was 42.7 months in the durvalumab arm and 42.1 months in the placebo arm. Median OS (95% CI) was 38.3 (28.9–42.8) months with durvalumab versus 32.5 (20.6–40.4) months with placebo (stratified HR, 0.87; 95% CI, 0.66–1.17; p = 0.346). A similar trend was observed in the ITT, though significance was not formally assessed per the hierarchical testing procedure (Fig. S5). The 12- and 24-month OS rates in the mITT were 80.9% and 60.7% with durvalumab versus 75.8% and 54.4% with placebo. ORR in the mITT was 27.6% with durvalumab versus 20.7% with placebo (odds ratio [OR] 1.51; 95% CI, 0.891–2.607; p = 0.128) (Table 2). Median DoR (95% CI) was not reached (16.6–not estimable [NE]) with durvalumab versus 37.6 (5.4–NE) months with placebo. The median TTDM in the mITT was 42.6 months (95% CI, 33.2–NE) with durvalumab and not reached (95% CI, 20.3–NE) with placebo (stratified HR, 1.06; 95% CI, 0.73–1.58; p = 0.769) (Fig. S6). PFS2 by investigator assessment per RECIST v1.1 in the mITT trended in favour of durvalumab; median PFS2 (95% CI) was 26.4 (22.1–36.0) months with durvalumab versus 19.5 (14.7–28.9) months with placebo (stratified HR, 0.86; 95% CI, 0.65–1.14; p = 0.275) (Fig. S7). Table 2Tumour response in the mITTmITT (N = 381)Durvalumab(n = 252)Placebo(n = 129)Measurable disease at baseline, n (%)221121Objective response, n (%)*†61 (27.6)25 (20.7) OR (95% CI) p-value1.51 (0.891, 2.607)0.128Best objective response, n (%)† Complete response*2 (0.9)2 (1.7) Partial response*59 (26.7)23 (19.0) Stable disease ≥ 8 weeks125 (56.6)67 (55.4) Progression30 (13.6)26 (21.5) RECIST progression24 (10.9)25 (20.7) Death6 (2.7)1 (0.8) Not evaluable5 (2.3)3 (2.5) Stable disease < 8 weeks1 (0.5)0 Incomplete post baseline assessments4 (1.8)3 (2.5)Median DoR (95% CI), months*‡NR (16.6–NE)37.6 (5.4–NE)BICR, blinded independent central review; CI, confidence interval; DoR, duration of response; mITT, modified intention-to-treat; NE, not estimable; NR, not reached; OR, odds ratio; RECIST, Response Evaluation Criteria in Solid TumorsResponse was determined by the RECIST-based assessment of the BICR. Patients who died with no evaluable RECIST assessments ≤ 17 weeks after randomisation were assigned to the ‘progression’ category. Patients who died with no evaluable RECIST assessments > 17 weeks after randomisation were assigned to the ‘not evaluable’ category*Patients did not require confirmation of response to be included†Percentages based on the number of patients with measurable disease at baseline‡DoR is defined as the time from date of first documented response until the first date of documented progression or death (in the absence of disease progression). Calculated using the Kaplan-Meier technique. CI for median DoR is derived based on the Brookmeyer-Crowley method with log-log transformation Tumour response in the mITT OR (95% CI) p-value 1.51 (0.891, 2.607) 0.128 BICR, blinded independent central review; CI, confidence interval; DoR, duration of response; mITT, modified intention-to-treat; NE, not estimable; NR, not reached; OR, odds ratio; RECIST, Response Evaluation Criteria in Solid Tumors Response was determined by the RECIST-based assessment of the BICR. Patients who died with no evaluable RECIST assessments ≤ 17 weeks after randomisation were assigned to the ‘progression’ category. Patients who died with no evaluable RECIST assessments > 17 weeks after randomisation were assigned to the ‘not evaluable’ category *Patients did not require confirmation of response to be included †Percentages based on the number of patients with measurable disease at baseline ‡DoR is defined as the time from date of first documented response until the first date of documented progression or death (in the absence of disease progression). Calculated using the Kaplan-Meier technique. CI for median DoR is derived based on the Brookmeyer-Crowley method with log-log transformation Safety Treatment-emergent AEs of any cause occurred in 94.8% of patients who received durvalumab and 83.6% of patients who received placebo (Table 3); maximum grade 3 or 4 AEs occurred in 26.9% and 23.9%, respectively. The most common any-grade AEs of any cause were pneumonitis or radiation pneumonitis (in 39.5% of patients in the durvalumab arm and 40.3% in the placebo arm), hypothyroidism (18.8% and 7.5%), pneumonia (18.8% and 11.2%), and anaemia (15.1% and 14.9%) (Table S2). The most common grade 3 or 4 AEs of any cause were pneumonia (in 5.9% of patients in the durvalumab arm and 5.2% in the placebo arm), pneumonitis or radiation pneumonitis (3.7% and 2.2%), and anaemia (2.2% and 1.5%) (Table S3). The most common AEs considered causally related to study treatment by the investigator were pneumonitis or radiation pneumonitis (in 18.5% of patients in the durvalumab arm and 11.9% in the placebo arm), hypothyroidism (15.5% and 7.5%), and hyperthyroidism (10.7% and 5.2%) (Table S4). Table 3Summary of adverse events in the safety analysis setSafety analysis set (N = 405)Durvalumab(n = 271)Placebo(n = 134)Any AE Causally related to study treatment*257 (94.8)172 (63.5)112 (83.6)53 (39.6)Any AE of maximum Grade 3 or 4 Causally related to study treatment*73 (26.9)23 (8.5)32 (23.9)5 (3.7)Any AE with outcome = death Causally related to study treatment*25 (9.2)†4 (1.5)§2 (1.5)‡0Any SAE Causally related to study treatment*104 (38.4)34 (12.5)45 (33.6)12 (9.0)Any AE leading to discontinuation of study treatment39 (14.4)11 (8.2)Any imAE¶75 (27.7)20 (14.9)Any imAE of maximum Grade 3 or 4¶11 (4.1)0Any AE of pneumonitis** or radiation pneumonitis107 (39.5)54 (40.3) Maximum Grade 3 or 410 (3.7)3 (2.2)AE, adverse event; imAE, immune-mediated adverse event; SAE, serious adverse eventPatients with multiple events in the same category are counted only once in that category. Patients with events in more than one category are counted once in each of those categories*As assessed by the investigator. Missing responses were counted as related†Fatal AEs in the durvalumab arm included acute coronary syndrome (n = 1), acute myocardial infarction (n = 2), cardiac arrest (n = 2), cardiac failure (n = 1), cerebral haemorrhage (n = 1), cerebral infarction (n = 1), cerebrovascular disorder (n = 1), COVID-19 pneumonia (n = 2), death (n = 3), haemoptysis (n = 1), interstitial lung disease (n = 1), laryngeal neoplasm (n = 1), pneumocystis jirovecii pneumonia (n = 1), pneumonia (n = 2), pneumonia bacterial (n = 1), pneumonitis (n = 3), pulmonary embolism (n = 1), respiratory failure (n = 1), and victim of homicide (n = 1). Patients with multiple events in the same preferred term are counted only once in that preferred term. Patients with events in more than one preferred term are counted once in each of those preferred terms‡Fatal AEs in the placebo arm included pneumonia bacterial (n = 1) and pneumonitis (n = 1)§Fatal AEs in the durvalumab arm considered possibly related to study treatment as assessed by the investigator were pneumonia (n = 1), pneumonitis (n = 3), interstitial lung disease (n = 1); note that one patient had both pneumonia and pneumonitis as AEs with outcome of death considered possibly related to study treatment as assessed by the investigator¶An imAE is defined as an AE of special interest that is associated with drug exposure, is consistent with an immune-mediated mechanism of action, and where there is no clear alternate aetiology**Pneumonitis is a grouped term that includes interstitial lung disease, immune-mediated lung disease, and pneumonitis Summary of adverse events in the safety analysis set Any AE Causally related to study treatment* 257 (94.8) 172 (63.5) 112 (83.6) 53 (39.6) Any AE of maximum Grade 3 or 4 Causally related to study treatment* 73 (26.9) 23 (8.5) 32 (23.9) 5 (3.7) Any AE with outcome = death Causally related to study treatment* 25 (9.2)† 4 (1.5)§ 2 (1.5)‡ 0 Any SAE Causally related to study treatment* 104 (38.4) 34 (12.5) 45 (33.6) 12 (9.0) AE, adverse event; imAE, immune-mediated adverse event; SAE, serious adverse event Patients with multiple events in the same category are counted only once in that category. Patients with events in more than one category are counted once in each of those categories *As assessed by the investigator. Missing responses were counted as related †Fatal AEs in the durvalumab arm included acute coronary syndrome (n = 1), acute myocardial infarction (n = 2), cardiac arrest (n = 2), cardiac failure (n = 1), cerebral haemorrhage (n = 1), cerebral infarction (n = 1), cerebrovascular disorder (n = 1), COVID-19 pneumonia (n = 2), death (n = 3), haemoptysis (n = 1), interstitial lung disease (n = 1), laryngeal neoplasm (n = 1), pneumocystis jirovecii pneumonia (n = 1), pneumonia (n = 2), pneumonia bacterial (n = 1), pneumonitis (n = 3), pulmonary embolism (n = 1), respiratory failure (n = 1), and victim of homicide (n = 1). Patients with multiple events in the same preferred term are counted only once in that preferred term. Patients with events in more than one preferred term are counted once in each of those preferred terms ‡Fatal AEs in the placebo arm included pneumonia bacterial (n = 1) and pneumonitis (n = 1) §Fatal AEs in the durvalumab arm considered possibly related to study treatment as assessed by the investigator were pneumonia (n = 1), pneumonitis (n = 3), interstitial lung disease (n = 1); note that one patient had both pneumonia and pneumonitis as AEs with outcome of death considered possibly related to study treatment as assessed by the investigator ¶An imAE is defined as an AE of special interest that is associated with drug exposure, is consistent with an immune-mediated mechanism of action, and where there is no clear alternate aetiology **Pneumonitis is a grouped term that includes interstitial lung disease, immune-mediated lung disease, and pneumonitis Fatal AEs of any-cause occurred in 25 (9.2%) patients in the durvalumab arm and 2 (1.5%) in the placebo arm (Table 3). Fatal AEs considered related to study treatment by the investigator occurred in 4 (1.5%) patients in the durvalumab arm (pneumonia and pneumonitis [n = 1], pneumonitis [n = 2], and interstitial lung disease [n = 1]) and 0 in the placebo arm. AEs led to discontinuation of study treatment in 14.4% of patients in the durvalumab arm and 8.2% in the placebo arm, most commonly pneumonitis or radiation pneumonitis, which led to discontinuation in 6.6% and 3.7% of patients in the durvalumab and placebo arms, respectively. Immune-mediated AEs (imAEs) of any grade, regardless of cause, were reported in 27.7% of patients in the durvalumab arm and 14.9% of in the placebo arm (Table S5); maximum grade 3 or 4 imAEs were reported in 4.1% and 0%, respectively. Pneumonitis or radiation pneumonitis occurred in similar proportions of patients who received durvalumab (39.5%) and placebo (40.3%), and most events were of grade 1 or 2 (Table S6). Discussion PACIFIC-5 met its primary endpoint with statistically significant and clinically meaningful improvement in PFS with durvalumab versus placebo among patients with unresectable stage III NSCLC without disease progression after either cCRT or sCRT. At this first interim analysis, there was a trend toward improved OS with durvalumab versus placebo. Other secondary endpoints also trended in favour of durvalumab versus placebo, though no difference was observed in TTDM between groups, likely due to the predominance of squamous histology, which has been associated with increased risk of a locoregional pattern of recurrence [24, 25]. The safety profile of durvalumab in PACIFIC-5 was generally consistent with the known safety profile of durvalumab, with no new safety signals despite treatment until progression [9, 10]. While an increased number of grade 5 AEs were reported in the durvalumab arm (9.2%, n = 25) compared with the placebo arm (1.5%, n = 2), the number of treatment-related deaths in the durvalumab arm was low (1.5%, n = 4) with no treatment-related deaths reported in the placebo arm. Despite the longer treatment duration in this study, these data are comparable to those reported for the phase III PACIFIC study (grade 5 treatment-related AEs were 1.5% in the durvalumab arm vs. 1.3% in the placebo arm) [9]. In the mITT population, PFS benefit with durvalumab was observed consistently in most of the prespecified subgroups (including prior CRT type [cCRT vs. sCRT]), with the exception of patients with tumors of non-squamous histology, patients whose tumor PD-L1 expression was < 1% on TCs, and patients who received cisplatin-based regimen of chemotherapy. For subgroups with non-squamous histology, PD-L1 TC < 1%, and receipt of prior cisplatin the placebo arms appeared to outperform the placebo arm of the mITT, while the durvalumab arms appeared to perform similarly to the durvalumab arm of the mITT. For example, median PFS for the placebo arms of the non-squamous, PD-L1 < 1%, and cisplatin subgroups was 19.9, 13.6, and 13.8 months, respectively, versus 6.5 months for the mITT overall, while median PFS for the durvalumab arms of the non-squamous, PD-L1 < 1%, and cisplatin subgroups was 15.0, 12.7, and 14.1 months, respectively, versus 14.0 months for the mITT overall. Imbalances in baseline demographics and disease characteristics between arms which favored placebo arm were likely to have impacted the observed differences in the treatment effect within the mITT (e.g., WHO/ECOG PS 0, stage IIIA disease, and non-squamous histology were more prevalent in the placebo arm of the mITT) or within subgroups. Additionally, subgroup analyses should be interpreted with caution given that the 95% CIs for HR cross one in each case, sample sizes are small relative to the mITT, and the study was not powered to assess statistical significance among these subgroups. It must also be noted that approximately 90% of the patients in both arms were male. Potential reasons for this may be the exclusion of patients with EGFR mutations, which are enriched in females, or that the incidence of lung cancer in men in China, which enrolled the majority of patients, is twice that reported in women [26, 27]. PACIFIC-5 supports the use of consolidation durvalumab after either cCRT or sCRT, consistent with the phase III GEMSTONE-301 trial (NCT03728556), which showed that consolidation treatment with the PD-L1 inhibitor sugemalimab improved PFS versus placebo among patients in China with unresectable stage III NSCLC and no progression after cCRT or sCRT (median PFS [95% CI], 9.0 [8.1–14.1] vs. 5.8 [4.2–6.6] months; HR [95% CI], 0.64 [0.48–0.85]), and with the phase II PACIFIC-6 trial (NCT03693300), which found that consolidation durvalumab had a manageable safety profile and encouraging efficacy (median PFS [95% CI], 10.9 [7.3–15.6] months) among patients with unresectable stage III NSCLC and no progression after sCRT [16, 28]. It is important to highlight that EGFR/ALK testing was not mandatory in GEMSTONE-301. Given that the study was predominantly conducted in Asian patients, where the prevalence of EGFR/ALK mutations is high, the lack of testing may have contributed to the differences in efficacy between the two studies. Despite this difference and with the caveat of cross-trial comparison, regional variation in clinical practice, and differences in study population, median PFS in the durvalumab arm of PACIFIC-5 (14.0 months) compares favourably to that observed in GEMSTONE-301 (10.5 months) and was similar to that observed in the PACIFIC trial (16.9 months) [11, 29]. In addition, median PFS for the placebo arms of PACIFIC-5 (6.5 months) and GEMSTONE-301 (6.2 months) performed similarly to both each other and to the placebo arm from the PACIFIC trial (5.6 months) [9, 11, 28]. Importantly, the fact that many patients in PACIFIC-5 received sCRT suggests that the population in PACIFIC-5 may have been less fit or more frail than in studies in which most or all patients received cCRT such as PACIFIC, as sCRT is often administered in lieu of cCRT due to concerns about tolerability [13–15]. Despite this, durvalumab maintains a manageable safety profile in this broader population, as evidenced by the general consistency of the safety profiles observed in PACIFIC-5 and PACIFIC and the similarity in rates of key safety parameters (e.g., maximum-grade 3 or 4 AEs, pneumonitis or radiation pneumonitis) between arms [9, 10]. Taken together, findings from PACIFIC-5, PACIFIC-6, PACIFIC, and real-world evidence support the use of durvalumab after either cCRT or sCRT [9, 10, 16, 30–34]. Despite the established impact of consolidation durvalumab after cCRT and the encouraging efficacy of durvalumab after sCRT for patients who do not receive cCRT, additional therapeutic options are required to further improve outcomes in this setting [35]. One potential strategy is initiating treatment with immunotherapies like durvalumab earlier, at the same time as CRT, though recent trials suggest limited benefit, if any, with this strategy [36, 37]. Another strategy is to combine PD-L1 inhibitors with other agents such monoclonal antibodies targeting TIGIT (domvanalimab), CD73 (oleclumab), or NKG2A (monalizumab) during consolidation treatment to harness potential synergy between disparate mechanisms of action. The phase II COAST trial (NCT NCT03822351) has shown encouraging results with durvalumab combined with either oleclumab or monolizumab, and results from two phase III trials in this setting are awaited: PACIFIC-8 (NCT05211895), assessing the efficacy and safety of durvalumab combined with domvanalimab, and PACIFIC-9 (NCT05221840), assessing the efficacy and safety of durvalumab plus either oleclumab or monalizumab [38–40]. Finally, the use of immunotherapy, alone or in combination with other agents (e.g., chemotherapy, anti-angiogenic therapy), as induction therapy followed by chemoradiotherapy or, when feasible, conversion to surgery is of ongoing scientific interest, with retrospective and early-phase clinical studies suggesting encouraging efficacy with regimens containing induction immunotherapy [41–48]. In conclusion, PACIFIC-5 met its primary endpoint of improved PFS with durvalumab versus placebo among a broader group of patients with unresectable stage III NSCLC than was included in the PACIFIC study, with no new safety signals despite treatment until progression. These data support the use of consolidation immunotherapy after either cCRT or sCRT. Supplementary Information Supplementary Material 1. Acknowledgements We thank the patients, their families and caregivers, the PACIFIC-5 independent data monitoring committee, and all PACIFIC-5 investigators and trial site coordinators. Medical writing support, under the direction of the authors, was provided by Eric Exner, MD, PhD (New York, NY, USA), of Ashfield MedComms, an Inizio company, and was funded by AstraZeneca. Abbreviations Adverse event Anaplastic lymphoma kinase Blinded independent central review Computed tomography Chemoradiotherapy Concurrent chemoradiotherapy Confidence interval Common Terminology Criteria for Adverse Events Data cut-off Duration of response Eastern Cooperative Oncology Group Epidermal growth factor receptor Hazard ratio Immune-mediated adverse events Intention-to-treat Modified intention-to-treat Magnetic resonance imaging National Cancer Institute Not estimable Non-small-cell lung cancer Odds ratio Objective response rate Overall survival Programmed cell death ligand-1 Positron emission tomography Progression-free survival Second progression Patient-reported outcomes Performance status Response Evaluation Criteria in Solid Tumors Sequential chemoradiotherapy Tumour cell Time to death or distant metastasis World Health Organization Author contributions Y-LW and LWu are co-first authors. Y-LW contributed to conceptualization, methodology, project administration, resources, and writing – reviewing and editing. LWu, NB, TC, HG, ZZ, C-LW, WZ, DL, ME, JS, YP, MK, MD, MS, and Y-CK contributed to investigation, project administration, resources, and writing – reviewing and editing. YY and RM contributed to conceptualization, data curation, project administration, validation, and writing – reviewing and editing. BZ contributed to conceptualization, data curation, formal analysis, project administration, software, validation, and writing – reviewing and editing. LWa contributed to conceptualization, methodology, project administration, resources, supervision, and writing – reviewing and editing. All authors reviewed and approved the final draft. Y-LW is the guarantor. The corresponding author attests that all listed authors meet authorship criteria and that no others meeting the criteria have been omitted. Funding This study was funded by AstraZeneca; clinicalTrials.gov number, NCT03706690. Data availability Data underlying the findings described in this manuscript may be obtained in accordance with AstraZeneca’s data sharing policy described at https://www.astrazenecaclinicaltrials.com/our-transparency-commitments/. Data for studies directly listed on Vivli can be requested through Vivli at www.vivli.org. Data for studies not listed on Vivli could be requested through Vivli at https://vivli.org/members/enquiries-about-studies-not-listed-on-the-vivli-platform/. The AstraZeneca Vivli member page is also available outlining further details: https://vivli.org/ourmember/astrazeneca/. Declarations Ethics approval and consent to participate The study protocol and amendments were reviewed and approved by the ethics committees at each centre. All the participants provided written informed consent. Consent for publication Not applicable. Competing interests Y-LW has received research grants (paid to the institution) from AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Jiangsu Hengrui, and Roche; and reports a speaker, consultant or advisor role for AstraZeneca, BeiGene, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Merck Sharp & Dohme, Pfizer, Roche, and Sanofi. TC has participated on an advisory board for AstraZeneca; has undertaken a coordinating PI role for Astellas Pharma, AstraZeneca, Merck KgaA, Merck Sharp & Dohme, Bristol Myers Squibb, Daiichi Sankyo, Johnson and Johnson, Amgen, Lilly, Stemline, Sandoz, Roche, BioNTech SE, Boehringer Ingelheim, Regeneron, Immuntep, AbbVie, and Duality; and reports an invited speaker role for Nobel, Astellas Pharma, Takeda, Daiichi Sankyo, Bristol Myers Squibb, Abdi Ibrahim, Johnson and Johnson, Deva, and Amgen. YP reports a principal investigator role for AstraZeneca; and speaker fees from AstraZeneca, Bristol Myers Squibb, Merck Sharp & Dohme, Pfizer, and Roche. MK reports an advisory role, participation on an advisory board, PI, coordinating PI, and local PI roles, speaker, consultant, or advisory fees, and an invited speaker role for Roche, Merck Sharp & Dohme, Bristol Myers Squibb, AstraZeneca, and Takeda. MANS reports participation on an advisory board and an invited speaker role for Roche, AstraZeneca, Pfizer, Novartis, Astellas, Bristol Myers Squibb, Merck Sharp & Dohme, Lilly, Gilead, Takeda, and Janssen. Y-CK reports research grants from AstraZeneca; speaker, consultant or advisor fees from AstraZeneca, Takeda, and Yuhan; and is a steering committee member for Yuhan. YY, RM and BZ are employees of and may own stock/stock options with AstraZeneca. The remaining authors have no conflicts of interest to disclose. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Yi-Long Wu and Lin Wu contributed equally to this work. Contributor Information Yi-Long Wu, Email: syylwu@live.cn. Luhua Wang, Email: wlhwq@yahoo.com. References Associated Data Supplementary Materials Supplementary Material 1. Data Availability Statement Data underlying the findings described in this manuscript may be obtained in accordance with AstraZeneca’s data sharing policy described at https://www.astrazenecaclinicaltrials.com/our-transparency-commitments/. Data for studies directly listed on Vivli can be requested through Vivli at www.vivli.org. Data for studies not listed on Vivli could be requested through Vivli at https://vivli.org/members/enquiries-about-studies-not-listed-on-the-vivli-platform/. The AstraZeneca Vivli member page is also available outlining further details: https://vivli.org/ourmember/astrazeneca/.